ABSTRACT
This review will briefly summarize glutamate receptor physiology and evaluate the evidence for glutamatergic
dysfunction in schizophrenia, focusing on postmortem findings, pharmacologic models, and clinical trials exam ining the effects of glutamatergic agents on the symptom atic manifestations of schizophrenia.
